Extraction method of quinoa active component and application of quinoa active component in preparation of antithrombotic drugs
Through specific extraction methods and isolation techniques, new active quinoa active components were obtained, and their roles were used in Toll-like receptors, C-type lectin and VEGF signaling pathways were solved, and the potential of quinoa in the field of anti-thrombosis in the prior art was solved. The unexamined problem has achieved effective treatment of thrombotic diseases.
Patent Information
- Application Number
- CN202411168553.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing quinoa extraction methods have not fully tapped their potential in the field of anti-thrombosis, and the existing traditional Chinese medicines have side effects and limited targets for the treatment of thrombotic diseases.
Soak the above-ground part of the citrus with 95% ethanol solution for 30 to 45 days, and separate it with a macroporous adsorption resin chromatography column to extract new citrus active components, such as Forskoditerpenoside C, Spinasaponin A, Ajugasalicioside F and Ochangoside analogues, and pass the Toll sample. Receptor signaling pathway, C-type lectin receptor signaling pathway, and VEGF signaling pathway exert antithrombotic effects.
The successful extraction of the active quinoa active component CA-C with antithrombotic activity significantly improved the effectiveness of antithrombotic drugs, especially in the treatment of atherosclerosis, cerebral thrombotic diseases and coronary heart disease.
Smart Images

Figure CN119015330A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of natural medicines, in particular to a method for extracting active components of Chenopodium album and application thereof in preparing antithrombotic drugs. Background Art
[0002] Chenopodium album L., also known as Chenopodium album and Chenopodium album, is a herbaceous plant of the Chenopodium genus of the Chenopodium family. Chenopodium is widely distributed in temperate and tropical regions and has medicinal, edible and feed values. At present, Chenopodium album has been found to have rich nutritional value, including dietary fiber, amino acids, vitamin C, β-carotene, and nutrients such as Fe, Zn, Mn and Cu that are beneficial to human health. Chenopodium album has been an excellent medicinal plant since ancient times, with antipruritic, analgesic, antioxidant, antibacterial and insecticidal effects. It is recorded in "Medicinal Plants in Desert Areas of China" that it can treat scabies, eczema, poisonous insect bites, vitiligo, dental caries, etc.
[0003] As a traditional Chinese medicine, Chenopodium contains abundant active substances such as phenols, alkaloids, flavonoids, terpenes, and sterols. At present, many papers have been published on the extraction and research of specific components in Chenopodium. For example, in the article "Ibrahlm LF, Kawashty SA, Baiuomy AR, et al. A comparative study of the flavonoids and some biological activities of two Chenopodium species [J]. Chem Nat Compd, 2007, 43 (1): 24-28.", Ibrahim LF et al. soaked Chenopodium dry powder in 70% ethanol / water at room temperature for 3 days to obtain a crude extract, and then separated and obtained 8 flavonoid glycosides such as kaempferol glycoside, quercetin glycoside and rhamnoside glycoside. In the article "Liu Songyan, Zhang Muxin, Wu Yuehong, et al. Chemical composition of flavonoids in quinoa [J]. Journal of Jilin University: Science Edition, 2011, 49(1): 149-152.", Liu Songyan et al. extracted 6 kg of quinoa whole herb powder with 95% ethanol for hot reflux extraction. After repeated silica gel column elution and separation, four flavonoid compounds were isolated from quinoa: quercetin 3-O-rutinoside, apigenin 6,8-di-C-β-D-glucoside, quercetin 3-O-[α-L-rhamnose (1→4)-α-L-rhamnose (1→6)-β-D-glucose], and isorhamnetin 3-O-[α-L-rhamnose (1→4)-α-L-rhamnose (1→6)-β-D-glucose]. In the article "Lavaud C, Voutquenne L, Bala P, et al. Saponins from Chenopodium album [J]. Fitoterapia, 2000, 71 (3): 338-340.", Lavaud C et al. isolated three saponins from the root of Chenopodium: calendulaside E and two oleanolic acids. In the article "Cutilllo F, D'abrosca B, Della Greca M, et al. Chenoalbicin, a novel cinnamic acid amide alkaloid from Chenopodium album L. [J]. Chem Biodivers, 2004, 1 (10): 1579-1583.", Cutillo F et al. extracted Chenopodium by methanol immersion, and subsequently separated and obtained 7 cinnamic acid amide alkaloids. It can be seen that Chenopodium has rich active substances. Different extraction and separation methods can be used to further explore the chemical components of Chenopodium, clarify its active substances, and then develop more applications in different fields.
[0004] In recent years, thrombotic diseases have become one of the most concerned chronic diseases in the world. Platelet overactivation plays a very important role in the occurrence and development of thrombotic diseases. After platelet activation, it will promote the adhesion and aggregation of platelets, forming platelet-rich thrombi, blocking arteries, affecting arterial blood flow, and thus causing thrombotic diseases. Thrombosis widely causes a variety of diseases, including atherosclerosis, cerebral thrombotic diseases, ischemic heart disease, ischemic stroke, coronary heart disease, deep vein thrombosis of lower extremities, etc. Therefore, inhibiting platelet activation is the main prevention and treatment of thrombotic diseases. In recent years, the research on the treatment of thrombotic diseases with traditional Chinese medicine has become more and more extensive. For example, Danshen, Panax notoginseng, Gastrodia elata, etc. have the effects of promoting blood circulation and removing blood stasis, dredging meridians, etc., and can be used to treat thrombosis; Traditional Chinese medicine has unique advantages in disease treatment due to its small side effects and multiple targets, and has a high development and utilization value.
[0005] In order to further explore the application potential of traditional Chinese medicine in the treatment of thrombotic diseases, the present invention takes Chenopodium album as the research object, intends to obtain more active ingredients in Chenopodium album through a new extraction method, and explores the application of active ingredients in anti-thrombosis. Summary of the invention
[0006] The invention provides a method for extracting active components of Chenopodium album and application of the method in preparing antithrombotic drugs. More new active components in Chenopodium album are extracted by adopting a specific extraction method, and the extracted active components of Chenopodium album have antithrombotic activity.
[0007] The technical solution of the present invention is as follows:
[0008] The invention discloses a method for extracting active components of Chenopodium album. The method comprises the following steps: extracting the above-ground part of Chenopodium album with a 95% (v / v) ethanol solution, soaking the above-ground part of Chenopodium album with the 95% (v / v) ethanol solution at 20-40°C for 30-45 days to obtain a total extract; extracting and removing fat from the total extract, separating the extract with a macroporous adsorption resin chromatography column, and eluting the extract with a 30% (v / v) or 60% (v / v) ethanol solution to obtain the active components of Chenopodium album.
[0009] Preferably, the method for extracting the active components of Chenopodium album comprises the following steps:
[0010] (1) taking the aerial part of Chenopodium album, crushing it into powder, adding 95% (v / v) ethanol solution to the powder, soaking it at 20-40° C. for 30-45 days to obtain an extract;
[0011] (2) Concentrating the extract under reduced pressure to obtain a total extract, adding distilled water to the total extract for suspension to obtain a suspension; extracting and degreasing the suspension, and concentrating the aqueous phase after extraction under reduced pressure to obtain an extract;
[0012] (3) dissolving the extract in distilled water, wet loading the sample, separating the extract using a macroporous adsorption resin chromatography column, and eluting the extract using a 30% (v / v) or 60% (v / v) ethanol solution as an eluent to obtain an eluate;
[0013] (4) The eluate is concentrated under reduced pressure and dried in vacuum to obtain the active components of Chenopodium album.
[0014] Preferably, in step (1), after soaking for 30 to 45 days, the soaking liquid is collected for later use; the powder is repeatedly soaked in 95% (v / v) ethanol solution for 2 to 4 times, each time for 5 to 7 days, and the soaking liquids are combined to obtain an extract.
[0015] Preferably, the particle size of the powder in step (1) is 20 to 40 meshes.
[0016] Preferably, the ratio between the powder and the 95% (v / v) ethanol solution in step (1) is 1:(5-10) (g / mL).
[0017] Preferably, the method of extracting and removing fat in step (2) is: extracting with petroleum ether of the same volume as the suspension, and the number of extractions is 3 to 5 times.
[0018] Preferably, the macroporous adsorption resin chromatography column in step (3) is a D101 macroporous adsorption resin chromatography column having a diameter-to-height ratio of 1:9.
[0019] Further preferably, the flow rate of the chromatography in step (3) is 2 BV·h -1 , eluted 6 to 10 BV.
[0020] Further preferably, the eluent in step (3) is a 60% (v / v) ethanol solution.
[0021] Application of the Chenopodium album active component in the preparation of antithrombotic drugs.
[0022] Among them, the active components of Chenopodium album exert anti-thrombotic effects through Toll-like receptor signaling pathway, C-type lectin receptor signaling pathway and VEGF signaling pathway.
[0023] Preferably, the active component of Chenopodium album is used in the preparation of drugs for treating atherosclerosis, cerebral thrombotic diseases, coronary heart disease and deep vein thrombosis of lower extremities.
[0024] Beneficial effects:
[0025] The invention provides a method for extracting active components of Chenopodium album and application of the method in preparing an antithrombotic drug. The active components in Chenopodium album are extracted by a specific extraction method, and not only compounds such as Forskoditerpenoside C, Spinasaponin A, Ajugasalicioside F and Ochangoside analogues which are first discovered in Chenopodium album are discovered, but also the obtained Chenopodium album active component CA-C has antithrombotic activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 UPLC-HRMS base peak ion chromatogram (BPC) of different active components of Chenopodium album in negative ion mode.
[0027] Figure 2 UPLC-HRMS base peak ion chromatogram (BPC) of different active components of Chenopodium album in positive ion mode.
[0028] Figure 3 UPLC liquid phase spectrum of different Chenopodium album active components - UV 254nm.
[0029] Figure 4 This is the identification result of the active component CA-C of Chenopodium album.
[0030] Figure 5 The effect of different active components of Chenopodium album on the red blood cell staining area in the heart of zebrafish.
[0031] Figure 6 The effect of different concentrations of CA-C, an active component of Chenopodium album, on the red blood cell staining area in the heart of zebrafish.
[0032] Figure 7 The volcano plot of differentially expressed genes.
[0033] Figure 8 This is the result of GO enrichment analysis.
[0034] Fig. 9 This is the result of KEGG enrichment analysis. DETAILED DESCRIPTION
[0035] The following is explained in conjunction with specific embodiments:
[0036] Example 1: Extraction of Chenopodium album active components
[0037] Follow these steps:
[0038] (1) About 50 kg (wet weight) of the above-ground part of quinoa was harvested, washed with distilled water to remove dust, placed in a constant temperature drying oven at 40° C. for 48 h, and then crushed through a 40-mesh sieve to obtain a powder; 10 kg of the powder was added with a 95% (v / v) ethanol solution at a solid-liquid ratio of 1:5 (g / mL), and soaked at 20° C. for 30 days, and the soaked liquid was collected for later use; the powder was repeatedly soaked in the 95% (v / v) ethanol solution for 2 times, each time for 5 days; and the soaked liquids were combined to obtain an extract.
[0039] (2) The extract was concentrated under reduced pressure using a rotary evaporator to obtain 712 g of an extract, namely, the total extract CA; distilled water was added to the total extract CA at a solid-liquid ratio of 1:8 (g / mL) to obtain a suspension; the suspension was extracted and degreased with the same volume of petroleum ether, and the extraction was performed 4 times. The aqueous phase after extraction was concentrated under reduced pressure to obtain 486 g of an extract.
[0040] (3) D101 macroporous adsorption resin was wet packed with a diameter-to-height ratio of 1:9; the extract was dissolved in distilled water and wet loaded with 0%, 30%, 60%, and 95% (v / v) ethanol solutions as eluents at a flow rate of 2 BV·h -1 , 8 BV of each isocratic elution was performed, and four eluates were collected.
[0041] (4) The eluate was concentrated under reduced pressure and dried in vacuum to obtain four corresponding Chenopodium album active components (CA-A, CA-B, CA-C, and CA-D) of different polarities.
[0042] Example 2: Extraction of Chenopodium album active components
[0043] Follow these steps:
[0044] (1) About 50 kg (wet weight) of the above-ground part of quinoa was harvested, washed with distilled water to remove dust, placed in a constant temperature drying oven at 40° C. for 48 h, and then crushed through a 30-mesh sieve to obtain a powder; 10 kg of the powder was added with a 95% (v / v) ethanol solution at a solid-liquid ratio of 1:5 (g / mL), and soaked at 30° C. for 40 days, and the soaked liquid was collected for later use; the powder was repeatedly soaked in the 95% (v / v) ethanol solution for 3 times, each time for 6 days; and the soaked liquids were combined to obtain an extract.
[0045] (2) The extract was concentrated under reduced pressure using a rotary evaporator to obtain 732 g of an extract, namely, the total extract CA; distilled water was added to the total extract CA at a solid-liquid ratio of 1:8 (g / mL) to obtain a suspension; the suspension was extracted and degreased with the same volume of petroleum ether, and the extraction was performed three times. The aqueous phase after extraction was concentrated under reduced pressure to obtain 504 g of an extract.
[0046] (3) D101 macroporous adsorption resin was wet packed with a diameter-to-height ratio of 1:9; the extract was dissolved in distilled water and wet loaded with 0%, 30%, 60%, and 95% (v / v) ethanol solutions as eluents at a flow rate of 2 BV·h -1 , 6 BV were eluted isocratically each time, and four eluates were collected.
[0047] (4) The eluate was concentrated under reduced pressure and dried in vacuum to obtain four corresponding Chenopodium album active components (CA-A, CA-B, CA-C, and CA-D) of different polarities.
[0048] Embodiment 3:
[0049] Extraction of Active Components from Chenopodium album
[0050] Follow these steps:
[0051] (1) About 50 kg (wet weight) of the above-ground part of quinoa was harvested, washed with distilled water to remove dust, placed in a constant temperature drying oven at 40° C. for 48 h, and then crushed through a 20-mesh sieve to obtain a powder; 10 kg of the powder was added with a 95% (v / v) ethanol solution at a solid-liquid ratio of 1:5 (g / mL), and soaked at 40° C. for 45 days to obtain an extract for later use; the powder was repeatedly soaked in the 95% (v / v) ethanol solution for 4 times, each time for 7 days; the liquids after soaking were combined to obtain an extract.
[0052] (2) The extract was concentrated under reduced pressure using a rotary evaporator to obtain 741 g of an extract, namely, the total extract CA; distilled water was added to the total extract CA at a solid-liquid ratio of 1:8 (g / mL) to obtain a suspension; the suspension was extracted and degreased with the same volume of petroleum ether, and the extraction was performed 4 times. The aqueous phase after extraction was concentrated under reduced pressure to obtain 519 g of an extract.
[0053] (3) D101 macroporous adsorption resin was wet packed with a diameter-to-height ratio of 1:9; the extract was dissolved in distilled water and wet loaded with 0%, 30%, 60%, and 95% (v / v) ethanol solutions as eluents at a flow rate of 2 BV·h -1 , 10 BV of each isocratic elution was performed, and four eluates were collected.
[0054] (4) The eluate was concentrated under reduced pressure and dried in vacuum to obtain four corresponding Chenopodium album active components (CA-A, CA-B, CA-C, and CA-D) of different polarities.
[0055] Example 4: Identification of active components of Chenopodium album
[0056] The components of the total extract CA of Chenopodium album obtained in Example 1 and four Chenopodium album active components (CA-A, CA-B, CA-C, CA-D) of different polarities were analyzed by ultra-performance liquid chromatography-high resolution mass spectrometry (UPLC-Q-TOF / MS). The results are as follows: Figures 1 to 3 shown.
[0057] according to Figures 1 to 3 The multi-level mass spectrometry information in the natural product high-resolution mass spectrometry database and related literature was combined to analyze the total extract CA of Chenopodium album and four Chenopodium album active components with different polarities (CA-A, CA-B, CA-C, CA-D). A total of 178 compounds were characterized, among which 25 compounds were identified in the Chenopodium album active component CA-C. Figure 4 shown.
[0058] Depend on Figure 4 It can be seen that the active component CA-C of Chenopodium album is mostly flavonoids, alkaloids, steroids or saponins, among which Forskoditerpenoside C (LCMS No. 126), Spinasaponin A (LCMS No. 93), Ajugasalicioside F (LCMS No. 62) and Ochangoside analogues (LCMS No. 47) are compounds first discovered in Chenopodium album. The above results show that the extraction method of the active component of Chenopodium album provided by the present invention can extract more new active components in Chenopodium album.
[0059] Example 5: Antithrombotic activity detection of Chenopodium album active components
[0060] The detection steps are as follows:
[0061] (1) The Chenopodium album total extract CA obtained in Example 1 and four Chenopodium album active components (CA-A, CA-B, CA-C, CA-D) of different polarities were dissolved in DMSO to prepare mother solutions with a concentration of 50 mg / mL for use.
[0062] (2) Select healthy AB wild-type zebrafish larvae at 3 dpf (days post fertilization) with normal development, randomly group them, and place them in the wells of a 24-well cell culture plate, with 10 fish in each well, and set up duplicate wells; each sample group is added with the mother solution of step (1) (the final concentration of each sample group is set to 50 μg / mL) to pretreat the zebrafish for 6 hours (placed in a constant temperature incubator at 28°C for culture), and at the same time set up a blank control group (pretreated with zebrafish culture water), a model group (pretreated with zebrafish culture water) and a positive control group (pretreated with aspirin at a final concentration of 22.5 μg / mL); then, except for the blank control group, the remaining zebrafish groups are treated with arachidonic acid at a final concentration of 24.35 μg / mL for 1.5 hours (continue to be placed in a constant temperature incubator at 28°C for culture). Then, each group of zebrafish was stained with o-dianisidine solution in the dark for 15 minutes, washed three times with fish water, and the red blood cell staining in the heart of the zebrafish was observed under a microscope. After the treatment, the zebrafish was taken out of the well, photographed under a microscope, and the red blood cell staining in the heart was statistically analyzed using Image J software. The results are as follows: Figure 5 As shown, Figure A is a representative photo of erythrocyte staining in the heart of zebrafish, and the red arrow indicates the heart of zebrafish (scale bar: 200 μm); Figure B is a bar graph of erythrocyte staining area in the heart of zebrafish. Compared with the blank group, #### P<0.0001, compared with the model group, **P<0.01, ***P<0.001, ****P<0.0001.
[0063] Depend on Figure 5 As shown in Figures A and B, the area of red blood cell staining in the heart of the model group was significantly reduced compared with the blank group, indicating that the platelets in the zebrafish treated with arachidonic acid were activated, forming aggregated thrombi, and the amount of blood returning to the heart was reduced, indicating that the zebrafish thrombosis model was successfully established. Compared with the model group, the area of red blood cell staining in the heart of zebrafish in the CA, CA-B and CA-C groups was significantly increased, with statistical differences; there was no statistical difference in the red blood cell staining in the heart of zebrafish in the CA-A group and the model group, and all zebrafish in the CA-D group died. The above results show that CA, CA-B and CA-C have anti-thrombotic activity, among which CA-C has the strongest activity, and CA-D has zebrafish toxicity.
[0064] Example 6: Antithrombotic gradient activity detection of Chenopodium album active component CA-C
[0065] (1) The Chenopodium album active component CA-C obtained in Example 1 was dissolved in DMSO to prepare a mother solution with a concentration of 50 mg / mL for later use.
[0066] (2) 3 dpf (days post fertilization) healthy AB wild-type zebrafish fry with normal development were selected, randomly divided into groups, and placed in the wells of a 24-well cell culture plate, with 10 fish in each well, and duplicate wells were set; the CA-C sample group was pretreated with the mother solution of step (1) (the final concentrations of the sample groups were set to 25 μg / mL, 50 μg / mL, and 75 μg / mL, respectively) for 6 h (cultured in a constant temperature incubator at 28°C), and a blank control group (pretreated with zebrafish culture water), a model group (pretreated with zebrafish culture water), and a positive control group (pretreated with aspirin at a final concentration of 22.5 μg / mL) were set up; then, except for the blank control group, the zebrafish in the remaining groups were treated with arachidonic acid at a final concentration of 24.35 μg / mL for 1.5 h (continued to be cultured in a constant temperature incubator at 28°C). Then, each group of zebrafish was stained with o-dianisidine solution in the dark for 15 minutes, washed three times with fish water, and the red blood cell staining in the heart of the zebrafish was observed under a microscope. After the treatment, the zebrafish was taken out of the well, photographed under a microscope, and the red blood cell staining in the heart was statistically analyzed using Image J software. The results are as follows: Figure 6 As shown, Figure A is a representative photo of erythrocyte staining in the heart of zebrafish, and the red arrow indicates the heart of zebrafish (scale bar: 200 μm); Figure B is a bar graph of erythrocyte staining area in the heart of zebrafish. Compared with the blank group, #### P<0.0001, compared with the model group, ****P<0.0001.
[0067] Depend on Figure 6 As shown in Figures A and B, the red blood cell staining area in the heart of the model group was significantly reduced compared with the blank group, indicating that the zebrafish thrombosis model was successfully established. Compared with the model group, the number of red blood cells in the heart of zebrafish in the 25μg / mL, 50μg / mL, and 75μg / mL CA-C groups increased, and the staining area increased, which was statistically significant; the above results showed that CA-C at concentrations of 25μg / mL, 50μg / mL, and 75μg / mL all showed good anti-thrombotic activity.
[0068] Example 7: Study on the anti-thrombotic mechanism of CA-C, an active component of Chenopodium album
[0069] (1) The Chenopodium album active component CA-C obtained in Example 1 was dissolved in DMSO to prepare a mother solution with a concentration of 50 mg / mL for later use.
[0070] (2) Preparation and collection of transcriptome sequencing samples
[0071] 3 dpf (days post fertilization) healthy AB wild-type zebrafish larvae with normal development were selected, randomly divided into groups, and placed in 6-well cell culture plate wells, with 30 fish in each well, and duplicate wells were set; the CA-C sample group was pretreated with the mother solution of step (1) (the final concentration of the sample group was set to 50 μg / mL) for 6 h (cultured in a 28°C constant temperature incubator), and a blank control group (pretreated with zebrafish culture water), a model group (pretreated with zebrafish culture water) and a positive control group (pretreated with aspirin at a final concentration of 22.5 μg / mL) were set at the same time; then, except for the blank control group, the zebrafish in the remaining groups were treated with arachidonic acid at a final concentration of 24.35 μg / mL for 1.5 h (continued to be cultured in a 28°C constant temperature incubator), and then the zebrafish were washed 3 times with deionized water and the samples were collected.
[0072] (3) RNA-Seq sequencing experimental methods and analysis methods
[0073] Total RNA was extracted using the TRIzol kit (Invitrogen, CA, USA); RNA purity and quantification were identified using a NanoDrop 2000 spectrophotometer (Thermo Scientific, USA), and RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA); a transcriptome library was constructed using the VAHTS Universal V5 RNA-seq Library Prep Kit according to the instructions; the library was sequenced using the Illumina Novaseq6000 sequencing platform, and 150 bp paired-end data were generated.
[0074] Differentially expressed genes were analyzed using DESeq2 software, and genes that met the thresholds of q value < 0.05 and foldchange > 2 or foldchange < 0.5 were defined as differentially expressed genes (DEGs). GO enrichment (https: / / ftp.ncbi.nih.gov / gene / DATA / gene2go.gz) and KEGG pathway analysis (https: / / www.genome.jp / kegg / ) were performed on differentially expressed genes (DEGs) to determine the significantly enriched GO terms and metabolic pathways of DEGs in different groups and samples.
[0075] (4) Differentially expressed gene results
[0076] The volcano plot can intuitively display the distribution of differentially expressed genes in each comparison combination. Figure 7The volcano map of differentially expressed genes is shown in Figure A, where Figure A shows the differentially expressed genes between the CA-C group and the model group, Figure B shows the differentially expressed genes between the model group and the blank control group, and Figure C shows the overlapping genes of the differentially expressed genes between Figure A and Figure B. Figure 7 As shown in Figure A, in the comparison between the CA-C group and the model group, 399 genes were upregulated and 2190 genes were downregulated. Figure 7 As shown in Figure B, in the comparison between the model group and the blank control group, there are 2977 up-regulated genes and 1285 down-regulated genes; Figure 7 As shown in Figure C, a total of 1542 differentially expressed genes were screened out between the model group and the blank control group, and between the CA-C group and the model group from the differentially expressed gene results in the volcano plot.
[0077] (5) GO enrichment analysis results
[0078] According to the results of GO enrichment analysis, GO entries corresponding to PopHits ≥ 5 in three categories [biological process (BP); cellular component (CC); molecular function (MF)] were screened, and the top 30 entries were selected according to the -log10p-value corresponding to each entry, sorted from large to small (the vertical axis in the figure is the GO entry name, and the horizontal axis is the -log10p-value. The lower the value, the more significant it is from a statistical point of view). The results are as follows Figure 8 As shown, Figure A shows the analysis results of the CA-C group and the model group, and Figure B shows the analysis results of the model group and the blank control group. The results showed that the gene functions involved in the anti-thrombotic effect of the active component CA-C of Chenopodium album include calcium ion binding, RNA polymerase II transcription regulatory region sequence-specific DNA binding, synaptic vesicle transport, phospholipase inhibitor activity, etc.
[0079] (6) KEGG enrichment analysis results
[0080] According to the results of KEGG enrichment analysis, the pathway entries corresponding to PopHits ≥ 5 were screened and sorted from large to small according to the -log10p-value corresponding to each entry (the bubble chart shows that the larger the bubble, the more differential protein-coding genes it contains, and the bubble color changes from blue-white-yellow-red. The smaller the enrichment p-value, the greater the significance). The top 20 pathways are as follows: Fig. 9 As shown, Figure A shows the analysis results of the CA-C group and the model group, and Figure B shows the analysis results of the model group and the blank control group. The results showed that the active component of Chenopodium album, CA-C, can exert anti-thrombotic effects through the Toll-like receptor signaling pathway, C-type lectin receptor signaling pathway, VEGF signaling pathway, etc.
Claims
1. A method for extracting active components from Chenopodium album, characterized in that: The method comprises the following steps: extracting the above-ground part of Chenopodium album with a 95% (v / v) ethanol solution, wherein the extract is soaked in the 95% (v / v) ethanol solution at 20-40°C for 30-45 days to obtain a total extract; extracting and removing fat from the total extract, separating the extract using a macroporous adsorption resin chromatography column, and eluting the extract using a 30% (v / v) or 60% (v / v) ethanol solution to obtain Chenopodium album active components.
2. The extraction method according to claim 1, characterized in that The specific steps include: (1) taking the aerial part of Chenopodium album, crushing it into powder, adding 95% (v / v) ethanol solution to the powder, soaking it at 20-40° C. for 30-45 days to obtain an extract; (2) Concentrating the extract under reduced pressure to obtain a total extract, adding distilled water to the total extract for suspension to obtain a suspension; extracting and degreasing the suspension, and concentrating the aqueous phase after extraction under reduced pressure to obtain an extract; (3) dissolving the extract in distilled water, wet loading the sample, separating the extract using a macroporous adsorption resin chromatography column, and eluting the extract using a 30% (v / v) or 60% (v / v) ethanol solution as an eluent to obtain an eluate; (4) The eluate is concentrated under reduced pressure and dried in vacuum to obtain the active component of Chenopodium album.
3. The extraction method according to claim 2, characterized in that In step (1), after soaking for 30 to 45 days, the soaking liquid is collected and set aside; the powder is repeatedly soaked in 95% (v / v) ethanol solution for 2 to 4 times, each time for 5 to 7 days, and the soaking liquids are combined to obtain an extract.
4. The extraction method according to claim 2, characterized in that The particle size of the powder in step (1) is 20 to 40 meshes.
5. The extraction method according to claim 2, characterized in that The ratio between the powder and the 95% (v / v) ethanol solution in step (1) is 1:(5-10) (g / mL).
6. The extraction method according to claim 2, characterized in that The method for extracting and removing fat in step (2) is: extracting with petroleum ether of the same volume as the suspension, and the number of extractions is 3 to 5 times.
7. The extraction method according to claim 2, characterized in that The macroporous adsorption resin chromatography column in step (3) is a D101 macroporous adsorption resin chromatography column.
8. The extraction method according to claim 2, characterized in that The eluent in step (3) is a 60% (v / v) ethanol solution.
9. Use of the Chenopodium album active component according to claim 1 in the preparation of antithrombotic drugs.
10. The use according to claim 9, characterized in that The active component of Chenopodium album is used in preparing medicines for treating atherosclerosis, cerebral thrombotic diseases, coronary heart disease and deep vein thrombosis of lower limbs.
Citation Information
Patent Citations
Application of anti-thrombotic extracts of rhizoma curcumae from Guangxi
CN106620543A
Method for extracting enriched polyphenol from chenopodium quinoa willd seeds
CN106723010A
Application of chenopodium formosanum extract on regulating expressions of NOS3 gene, PLAT gene, F3 gene and / or SERPINE1 gene
CN108201544A
